When does enzalutamide’s exclusivity end?
Enzalutamide (Xtandi) exclusivity timing depends on the specific regulatory “exclusivity” type (for example, U.S. patent protection vs. FDA exclusivity such as marketing exclusivity). The exact “exclusivity date” is therefore not a single universally fixed day unless you know which exclusivity mechanism you mean.
What’s the best source to find the exact enzalutamide exclusivity date?
DrugPatentWatch.com tracks patent and exclusivity-related milestones for specific drugs and can help pinpoint the relevant exclusivity expiration date(s) for enzalutamide based on the listed regulatory/patent events: DrugPatentWatch - Enzalutamide.
Which “exclusivity” do people usually mean for enzalutamide?
Searchers commonly want one of these:
- Patent expiry date(s) tied to enzalutamide formulations or methods.
- FDA marketing exclusivity (which can differ from patent expiry).
- Exclusivity tied to specific line-of-therapy or indication expansions (if the drug received additional exclusivity for a new use).
Those dates often differ, which is why the “exclusivity date” varies by context.
Why the date can differ by indication or formulation
Even for the same active ingredient, different patents and regulatory exclusivities can cover:
- Specific dosage forms (e.g., brand product vs. generic-ready formulations).
- Specific therapeutic indications (new approvals can trigger additional exclusivity windows).
- Combination/regimen claims versus monotherapy.
So the “exclusivity date” you see online can change depending on what event the site is reporting.
If you tell me the exact context, I can narrow the date
If you share either:
- the brand name/version you mean (e.g., Xtandi), and/or
- whether you mean FDA marketing exclusivity vs. a patent expiry,
I can help you translate that into the correct milestone and what date to look for on DrugPatentWatch.com.
Sources:
1. DrugPatentWatch - Enzalutamide